Overview
The Terminator Seeds theory grew out of a real patent, which is why it has outlasted most of the anti-GMO claims of its period. The patent exists, it does what critics said it did, and one of the two organisations that owned it was an agency of the United States government.
What happened next is the part usually left out. The technology was never commercialised, the company most associated with it never owned the patent, and the international body that acted on it issued a recommendation rather than a ban. Those three facts are the difference between the documented controversy and the theory built on top of it.
The patent
US Patent 5,723,765, "Control of plant gene expression," was filed on 7 June 1995 and granted on 3 March 1998. Its named inventors are Melvin John Oliver, Jerry Edwin Quisenberry, Norma Lee Glover Trolinder and Don Lee Keim, and its original assignees are Delta and Pine Land Company and the United States Department of Agriculture.
The abstract describes a method for producing a genetically modified plant carrying "a first gene whose expression results in an altered plant phenotype linked to a transiently active promoter" — in plain terms, a genetic switch that can be triggered so that the seed a farmer harvests will not grow.
The joint assignment is the detail that gives the story its force. This was not a corporation quietly patenting something on its own. A public agricultural research agency co-owned a patent for making seed sterile, which meant the objection could be raised in a public forum against a public body, and it was.
The class of technique became known as Genetic Use Restriction Technologies, or GURTs. "Terminator" was a name given to it by critics, not by the people who filed the patent.
The category is broader than the nickname suggests, and the distinction gets lost in most retellings. V-GURTs are variety-specific — the version that renders harvested seed non-viable, and the one the argument is actually about. T-GURTs are trait-specific: the plant reproduces normally, but an engineered trait such as pest resistance stays switched off unless the farmer applies a chemical activator. The second is a licensing mechanism rather than a sterility one, and it is not what "Terminator" describes.
Monsanto is not on the patent
The company's name is attached to the story so firmly that the underlying document surprises people: Monsanto is not an assignee, an applicant or an inventor of US 5,723,765.
Its connection is corporate rather than technical. Monsanto moved to acquire Delta and Pine Land Company in 1998, which would have brought the patent with it. The deal did not complete. The acquisition eventually went through in 2007, bringing the patents with it — but by then the company had publicly committed not to use the technology, and the original patent has since expired.
That commitment is a document too. On 4 October 1999, Monsanto's chief executive Robert Shapiro wrote an open letter to Gordon Conway, president of the Rockefeller Foundation, stating: "I am writing to let you know that we are making a public commitment not to commercialize sterile seed technologies, such as the one dubbed 'Terminator.'" He gave the reason as "input from you and a wide range of other experts and stakeholders, including our very important grower constituency."
Campaign groups claimed the credit, and the sequence supports them: sustained public pressure produced a written corporate undertaking within about eighteen months of the patent being granted.
What the Convention on Biological Diversity actually did
The international response is often described as a global ban. It was not.
At its fifth Conference of the Parties, on 26 May 2000, the Convention on Biological Diversity adopted decision V/5. Paragraph 23 recommends that, "in the current absence of reliable data on genetic use restriction technologies, without which there is an inadequate basis on which to assess their potential risks, and in accordance with the precautionary approach, products incorporating such technologies should not be approved by Parties for field testing until appropriate scientific data can justify such testing, and for commercial use until appropriate, authorized and strictly controlled scientific assessments" had been carried out.
That is a recommendation to member states, framed explicitly as a response to missing data rather than to demonstrated harm, and conditional on assessments that could in principle be satisfied. It is a moratorium in effect and by agreement, not a prohibition in law.
It has also been revisited rather than left to lapse. At its eighth meeting in 2006 the Conference of the Parties adopted decision VIII/23, which opens its section on the subject by reaffirming "decision V/5, section III (Genetic use restriction technologies)" — the same recommendation, restated six years on, alongside language about farmers' rights to preserve seed under traditional cultivation.
The distinction matters in both directions. Critics who call it a ban overstate what was decided; defenders who call it a formality understate a recommendation that has been deliberately renewed and has shaped what no company has attempted to sell for twenty-five years.
The claim that outgrew the evidence
The original objection was economic and is coherent on its own terms: seed that cannot be replanted makes a farmer buy again every season, and in agricultural systems built on saved seed that is a structural change, not a product feature. That argument needs no hidden motive and was made openly by farmers' organisations, seed-sovereignty campaigners and national delegations.
The larger version holds that sterile-seed technology was a step toward reducing human fertility through the food supply — that the same logic could be turned on people.
This is where the documentary trail stops. The technology was never commercialised anywhere, by anyone. There are no Terminator seeds in agriculture and therefore none in the food supply, which leaves the human-sterility claim without a mechanism, a product, or a population that could have been exposed to it. The claim also asks a genetic switch that prevents a plant embryo from developing to do something entirely different in an animal that eats the resulting grain, which is not how either process works.
What makes the extension durable is that its first step is true. A patent for engineered sterility did exist, a government agency did co-own it, and a corporation did try to buy the company holding it. Each of those is checkable, and someone who has checked them is understandably less inclined to stop at the point where the record does.
Why it persists
The theory occupies unusually solid ground for a conspiracy claim: a patent number, a corporate letter, an intergovernmental decision, and named institutions on every side.
It persists partly because the reassurance offered against it is weaker than it sounds. "The technology was never commercialised" is a statement about what has happened so far, not a guarantee, and the patent did not disappear — it expired in the ordinary way. The CBD recommendation is renewable rather than permanent, and has been revisited at subsequent meetings.
So the honest summary is narrower than either side usually wants. A method of engineering seed sterility was patented, co-owned by the USDA, never brought to market, publicly renounced by the company most blamed for it, and placed under an international moratorium that remains a recommendation. Everything beyond that — particularly anything about human fertility — is an extrapolation from a technology that was never deployed.